Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sanhuang Yishen Capsules plus semaglutide in diabetic nephropathy
ChiCTR2400079569Phase 4Not yet recruiting
- Sponsor
- Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine
- Start
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of semaglutide and Sanhuang Yishen Capsule in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine. Primary endpoints: glycosylated hemoglobin, urinary microalbumin/creatinine ratio and 3 more. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
semaglutideSanhuang Yishen Capsule
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400079569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079569.